Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Baxter International, Inc.
Sales grew 6% while earnings declined for pharma company
May 14th, 2003
Baxter International, Inc., (BAX) reported that it achieved its sales and diluted earnings per share (EPS) goals for the first quarter of 2003. Baxter's sales grew 6% in the first quarter, while earnings declined as a result of product mix and competitive pricing in the plasma market. Baxter's sales from continuing operations in the quarter rose to $2.0 billion, up from $1.88 billion reported for the same period last year. The increase in sales for the first quarter included a 4 percentage-point benefit from foreign exchange. Sales within the United States grew 4% to $956 million, while sales outside the United States grew 9% to $1.04 billion (or...
Source: Biotech Week (2003-05-14)
|
